

A provider's guide to helping patients save on Nystatin/Triamcinolone. Learn about discount programs, generic pricing, and cost conversations.
As a prescriber, you know that even an inexpensive medication becomes a barrier if the patient can't afford it. Nystatin/Triamcinolone — a combination antifungal/corticosteroid cream or ointment used for cutaneous candidiasis — is available generically and is relatively affordable compared to many prescriptions. But "relatively affordable" still means $15 to $80 out of pocket for patients without insurance or with high-deductible plans. For patients on fixed incomes or managing multiple prescriptions, that cost can lead to treatment non-adherence, incomplete courses, or stretching the medication thinner than recommended.
This guide covers the current pricing landscape and the tools available to help your patients access Nystatin/Triamcinolone at the lowest possible cost.
Nystatin/Triamcinolone is available only as a generic — the original brand names (Mycolog-II, Mytrex) have been discontinued. Current cash pricing ranges:
Insurance coverage is generally favorable. Most formularies list Nystatin/Triamcinolone as Tier 1 or Tier 2, with copays typically ranging from $0–$15. Prior authorization is rarely required, and step therapy mandates are uncommon for this combination product.
However, the patients who need cost help most are often those without insurance, those in the Medicaid gap, or those with plans that have high deductibles for even generic medications.
For uninsured or underinsured patients, prescription discount cards can reduce Nystatin/Triamcinolone costs significantly — often to $10–$25 for a 30g tube. These programs are free for patients and don't require insurance enrollment:
A key point for your workflow: discount cards cannot be combined with insurance copays. The pharmacist will run whichever option is cheaper for the patient. You can note on the prescription that the patient may use a discount card if it results in a lower price than their insurance copay.
Because Nystatin/Triamcinolone is only available as a generic from multiple manufacturers (Taro, Perrigo, Glenmark, Actavis, etc.), there are no manufacturer-sponsored patient assistance programs or savings cards for this medication. This is typical for mature generics without active brand marketing.
However, patients facing financial hardship have other options:
Since Nystatin/Triamcinolone is already available generically, the primary cost-saving strategy is pharmacy shopping rather than therapeutic substitution. However, if cost remains a barrier or the combination product is unavailable, consider:
When considering alternatives, remember that Nystatin specifically targets Candida species. If the clinical picture suggests dermatophyte infection rather than candidiasis, a different antifungal (clotrimazole, terbinafine) would be more appropriate regardless of cost.
Many providers find cost discussions uncomfortable or time-consuming, but brief interventions can make a meaningful difference:
Nystatin/Triamcinolone occasionally experiences local stock-outs. If patients report difficulty filling their prescription:
For more on availability, see our guide on the Nystatin/Triamcinolone shortage and what providers need to know.
Nystatin/Triamcinolone is one of the more affordable prescriptions in dermatology, but "affordable" is relative to each patient's situation. The most impactful thing you can do as a prescriber is ask about cost barriers proactively and point patients toward the free tools — discount cards, Medfinder, and assistance program databases — that can bridge the gap. For a patient-facing version of this information, share our guide on how to save money on Nystatin/Triamcinolone.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.